follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
second-quart world-wide sale billion increas sale increas
exclud neg impact foreign exchang growth driven oncolog human health
keytruda sale grew billion exclud impact foreign exchang sale
human health vaccin sale grew billion exclud impact foreign
second-quart ep second-quart non- ep
compani narrow rais full-year revenu rang billion
billion includ neg impact foreign exchang slightli
compani narrow reduc full-year ep rang
reflect charg relat acquisit peloton therapeut
compani narrow rais full-year non-gaap ep rang
includ slightli neg impact foreign exchang
keytruda combin chemotherapi primari endpoint patholog complet respons
pcr pivot phase trial neoadjuv therapi patient triple-neg
tuesday juli edt
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result second quarter
science-l strategi execut across key growth pillar driven anoth quarter acceler
revenu growth strength across global portfolio said kenneth frazier chairman chief execut
offic merck remain confid innov product signific pipelin opportun continu
deliv strong result provid sustain valu patient sharehold
world-wide sale billion second quarter increas compar second
million except ep amount
non-gaap net incom exclud certain
non-gaap ep exclud certain
refer tabl page
quarter exclud neg impact foreign exchang world-wide sale grew
gener accept account principl earn per share assum dilut ep
second quarter non-gaap ep second quarter exclud acquisition-
divestiture-rel cost restructur cost certain item year-to-d result found attach
merck continu advanc develop program keytruda pembrolizumab compani
therapi lynparza olaparib parp inhibitor co-develop co-commerci astrazeneca
lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor co-develop co-
commerci eisai co ltd eisai
merck announc food drug administr fda approv keytruda follow
first-lin treatment patient metastat unresect recurr head neck
squamou cell carcinoma hnscc monotherapi patient whose tumor express
combin posit score combin platinum fluorouracil fu
commonli use chemotherapi regimen base overal surviv result
trial
treatment patient metastat small cell lung cancer sclc diseas progress
platinum-bas chemotherapi least one prior line therapi base result
trial
merck announc european medicin agenc ema adopt posit opinion keytruda
combin axitinib first-lin treatment advanc renal cell carcinoma rcc base
find pivot trial
merck announc fda accept review six supplement biolog licens applic
sbla updat dose frequenc keytruda includ every-six-week dose
schedul option certain monotherapi indic fda set pdufa date feb
merck present five-year surviv data keytruda advanc non-smal cell lung cancer nsclc
first keynot trial phase updat overal surviv analysi new data
diseas progress next-lin treatment progression-fre trial
metastat nonsquam nsclc american societi clinic oncolog annual
merck announc phase trial investig keytruda combin
chemotherapi met primari endpoint patholog complet respons pcr follow neoadjuv
part neoadjuvant/adjuv studi regimen patient triple-neg breast cancer tnbc
trial continu evalu dual-primari endpoint event-fre surviv ef result
present upcom medic congress
merck astrazeneca announc approv lynparza japan separ european
union use first-lin mainten therapi patient brca-mut advanc ovarian cancer
base result phase trial lynparza parp inhibitor approv
indic parp inhibitor approv japan
merck astrazeneca present result phase polo trial patient germlin brca-
mutat metastat pancreat cancer whose diseas progress follow platinum-bas
chemotherapi trial lynparza reduc risk diseas progress death nearli half
result present annual meet simultan publish new
england journal medicin
merck astrazeneca also present result phase trial annual
meet studi evalu object respons rate lynparza compar chemotherapi
patient platinum-sensit relaps germlin advanc ovarian cancer
receiv two prior line chemotherapi
merck eisai announc receipt breakthrough therapi design fda
keytruda plu lenvima combin regimen potenti first-lin treatment patient advanc
unresect hepatocellular carcinoma amen loco-region treatment repres third
merck announc center diseas control prevent cdc advisori committe
immun practic acip vote recommend human papillomaviru hpv vaccin
gardasil human papillomaviru vaccin recombin base share clinic decis
make individu age adequ vaccin acip also vote
expand routin catch-up recommend male age adequ
merck present phase trial result compani investig pneumococc
conjug vaccin demonstr noninferior pcv share serotyp immun
respons two addit disease-caus serotyp healthi infant result
present european societi paediatr infecti diseas espid current phase
hiv hospit acut
merck present late-break data islatravir formerli compani investig
nucleosid revers transcriptas transloc inhibitor nrtti develop prevent
treatment infect recent aid societi confer hiv scienc ia
includ
phase result demonstr combin islatravir doravirin maintain antivir
activ treatment-nav adult week base result compani plan
initi phase program evalu islatravir combin doravirin across divers patient
popul
phase result evalu pharmacokinet safeti prototyp subderm drug-elut
implant extend administr islatravir healthi volunt hiv pre-exposur
merck announc fda approv expand use zerbaxa ceftolozan tazobactam
treatment adult hospital-acquir ventilator-associ bacteri pneumonia habp/vabp
separ announc ema adopt posit opinion recommend zerbaxa habp vabp
consider european commiss
merck announc fda approv recarbrio imipenem cilastatin relebactam treatment
adult complic urinari tract complic intra-abdomin bacteri infect limit
altern treatment option avail
merck acquir peloton therapeut peloton biopharmaceut compani focus develop
novel small molecul therapeut candid target hypoxia-induc
treatment patient cancer non-oncolog diseas includ novel oral inhibitor
late-stag develop rcc acquisit close juli
merck acquir gain portfolio investig antibodi target tgf
potenti applic treatment cancer fibrosi autoimmun diseas acquisit close
merck acquir immun design provid potenti next-gener vivo approach enabl bodi
immun system fight diseas acquisit close april
follow tabl reflect sale compani top pharmaceut product well sale anim health
million
proquad m-m-r ii
second-quart pharmaceut sale billion increas compar second quarter
exclud unfavor effect foreign exchang sale grew second quarter increas
driven primarili growth oncolog vaccin partial off-set on-going impact loss market
exclus sever product pharmaceut sale repres total sale quarter
perform intern market led china pharmaceut sale million repres
growth compar second quarter driven oncolog vaccin exclud
unfavor effect foreign exchang pharmaceut sale china grew
growth oncolog larg driven nearli billion increas sale keytruda billion reflect
strong momentum nsclc indic well continu uptak indic includ recent
launch rcc adjuv melanoma indic along growth lynparza lenvima
growth vaccin reflect higher sale gardasil papillomaviru quadrival type
vaccin recombin gardasil vaccin prevent certain cancer diseas caus hpv
primarili due public sector buy pattern demand price unit state on-going commerci
launch china higher demand europ driven primarili increas vaccin rate boy girl
also contribut sale growth
growth pediatr vaccin driven m-m-r ii measl mump rubella viru vaccin live vaccin
help prevent measl mump rubella varivax varicella viru vaccin live vaccin help prevent
chickenpox proquad measl mump rubella varicella viru vaccin live combin vaccin
help protect measl mump rubella varicella reflect higher demand includ private-sector buy-in
price unit state govern tender latin america higher demand europ
perform hospit acut care reflect strong demand unit state bridion sugammadex inject
mg/ml medicin revers neuromuscular blockad induc rocuronium bromid vecuronium
bromid adult undergo surgeri on-going launch prevymi letermovir medicin
prevent cytomegaloviru cmv infect diseas adult cmv-seroposit recipi allogen
pharmaceut sale growth quarter partial off-set on-going impact loss market
exclus zetia ezetimib vytorin ezetimibe/simvastatin invanz ertapenem sodium
remicad infliximab addit declin sale januvia sitagliptin janumet sitagliptin
metformin reflect continu price pressur unit state off-set higher demand
anim sale total billion second quarter increas compar second
quarter exclud unfavor effect foreign exchang anim health sale grew growth
second quarter primarili driven livestock predominantli due product acquir antelliq acquisit
companion anim sale perform reflect volum growth vaccin insulin product partial off-set
time custom purchas prior year bravecto fluralan line product parasit control
anim segment profit million second quarter decreas compar
million second quarter primarili reflect unfavor impact foreign
second-quart expens ep relat inform
tabl present select expens inform
million
sale
sell gener administr
research develop
sale
sell gener administr
research develop
gaap expens ep relat inform
gross margin second quarter compar second quarter
increas gross margin second quarter primarili driven lower acquisition- divestiture-
relat cost favor product mix lower amort intang asset relat collabor partial
off-set higher restructur cost
sell gener administr expens billion second quarter increas
acquisition-
compar second quarter increas primarili reflect higher administr acquisition-
divestiture-rel restructur promot cost partial off-set favor effect foreign exchang
research develop expens billion second quarter declin
compar second quarter declin driven primarili lower expens relat busi
develop transact larg reflect million charg record second quarter relat
viralyt limit acquisit declin partial off-set higher expens relat clinic develop
increas invest discoveri research earli drug develop
incom expens net million expens second quarter compar million
incom second quarter incom expens net second quarter reflect
impair charg lower incom invest equiti secur
gaap ep second quarter compar second quarter
non-gaap expens ep relat inform
non-gaap gross margin second quarter compar second quarter
increas non-gaap gross margin reflect favor product mix lower amort intang
asset relat collabor
non-gaap sell gener administr expens billion second quarter
increas compar second quarter increas reflect higher administr promot cost
partial off-set favor effect foreign exchang
non-gaap expens billion second quarter increas compar second
quarter increas reflect higher expens relat clinic develop invest discoveri
research earli drug develop well busi develop transact
non-gaap incom expens net million incom second quarter compar
million incom second quarter driven primarili lower incom invest equiti
non-gaap ep second quarter compar second quarter
reconcili non- net incom ep provid tabl follow
million except ep amount
non-gaap ep exclud item list
non-gaap net incom exclud item list
decreas increas net incom due exclud item
acquisition- divestiture-rel
charg acquisit viralyt
net decreas increas incom tax
acquisition- divestiture-rel cost attribut non-controlling interest
decreas increas net incom
merck narrow rais full-year revenu rang billion billion includ
neg impact foreign exchang slightli mid-juli exchang rate
merck narrow reduc full-year ep rang reduct
ep rang primarili reflect inclus approxim billion charg relat acquisit
peloton merck narrow rais full-year non-gaap ep rang
includ slightli neg impact foreign exchang mid-juli exchang rate non-gaap rang
exclud acquisition- divestiture-rel cost cost relat restructur program net benefit
settlement certain feder incom tax matter charg acquisit peloton certain item
follow tabl summar compani full year financi guidanc
billion
billion
higher mid-singl digit rate
oper expens higher low-singl digit rate
compani non-gaap adjust revenu
ep guidanc assum share count assum dilut approxim billion share
reconcili anticip ep non- ep item exclud non- ep
provid tabl
million except ep amount
non-gaap ep exclud item list
acquisition- divestiture-rel
charg acquisit peloton
net decreas increas incom tax
decreas increas net incom
expect full-year effect tax rate reflect net favor impact approxim
percentag point item
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
today merck global health care leader work help world well merck known msd outsid
unit state canada prescript medicin vaccin biolog therapi anim health
product merck work custom oper countri deliv innov health solut
merck also demonstr commit increas access health care far-reach polici program
partnership
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
aenova group one world lead compani pharmaceut healthcar industri europ
aenova one lead contract manufactur rang servic cover entir valu chain
develop manufactur common dosag form solid semi-solid liquid product group
medicin dietari supplement group oper site nine european countri asia usa
twelv site headquart locat germani aenova employe
 braun one world lead healthcar supplier braun four divis orient product
servic toward differ medic field hospit surgeri privat practic medic care doctor offic
bayer innov compani histori core compet field health care
agricultur develop new molecul use innov product solut improv health
human anim plant bayer research develop activ base profound understand
biochem process live organ
boehring ingelheim group one world lead pharmaceut compani headquart
ingelheim germani boehring ingelheim oper global affili employe
focu family-own compani found research develop manufactur market
new medic high therapeut valu human veterinari medicin
umbrella tecdax-list compani carl zeiss meditec ag one world lead
medic technolog compani medic technolog activ zeiss bundl carl zeiss ag hold
interest carl zeiss meditec ag jena germani parent compani carl zeiss meditec
group compris addit subsidiari carl zeiss meditec inc carl zeiss meditec iberia
desitin arzneimittel gmbh activ intern germani switzerland scandinavia eastern europ level
hamburg plant produc sophist product treatment neurolog psychiatr ill
offer larg number establish innov product especi core indic epilepsi
parkinson syndrom optim pharmacotherapi continu develop cooper
future-ori compani treat diseas central nervou system one desitin main area
activ invest
freseniu global healthcar group offer high-qual product servic dialysi hospit
outpati treatment employe countri around globe annual sale
exceed billion freseniu one world lead healthcar compani freseniu group includ
four independ oper busi segment one activ major growth area healthcar freseniu
medic world leader treat peopl chronic kidney failur freseniu helio germani largest
hospit oper freseniu kabi suppli essenti drug clinic nutrit product medic devic servic
help critic chronic ill patient freseniu vame plan develop manag healthcar facil
freseniu medic world largest integr provid product servic individu undergo
dialysi chronic kidney failur condit affect around million individu world-wide
network dialysi clinic north america europ latin america asia-pacif africa freseniu
medic provid dialysi treatment patient around globe freseniu medic also
world lead provid dialysi product hemodialysi machin dialyz relat dispos
grnenthal group independ family-own intern research-bas pharmaceut compani
headquart aachen germani grnenthal one five remain research-ori pharmaceut
compani headquart germani sustain invest research develop research
develop cost amount percent revenu grnenthal research develop
strategi concentr select field therapi state-of-the-art technolog compani focus
discov new way treat pain better effect fewer side-effect current therapi
human healthcar togeth
merz pharma independ intern aesthet neurotoxin compani research
develop capabl continu growth market leadership aesthet neurotoxin result
drive innov along focus strateg acquisit continu expand across area
busi due focus purpos approach includ organ inorgan growth privately-
held family-own compani histori believ take long-term view
morphosi develop hucal success antibodi librari technolog pharmaceut industri
success appli patent technolog morphosi becom leader field
therapeut antibodi one
pharmaceut partner morphosi built therapeut pipelin human antibodi drug
candid treatment cancer rheumatoid arthriti alzheim diseas name
on-going commit new antibodi technolog drug develop morphosi focus make
healthcar product tomorrow morphosi list frankfurt stock exchang symbol mor
hartmann group one lead european provid medic hygien product core
compet wound treatment wound dress negative-pressur wound therapi conform bandag
plaster incontin care dispos incontin brief pad well product skin care case
incontin infect protect surgic drape oper theatr cloth dispos surgic
instrument disinfect portfolio supplement product compress therapi first aid
compani headquart heidenheim germani whose prioriti market europ oper around
world employe hartmann group gener sale eur million
engin innov employ peopl compani provid healthcar germani
harmon qualiti medic care sound busi model good busi judgment
tada publicli trade intern compani focu healthcar market
perfect combin tradit innov attract cost
germani best intern locat research product distribut pharmaceut
except high level direct access intern renown scientist outstand research unit major
pharmaceut market make germani uniqu busi locat develop world popul
structur creat new challeng lead increas demand pharmaceut togeth
signific advanc medic biotechnolog research give pharmaceut industri new impetu
addit central locat heart europ germani offer excel well-develop nationwid
infrastructur modern transport network work coordin high-qual commun
energi infrastructur hundr thousand highli qualifi worker area medic technolog
pharmaceut technolog mechan engin enabl compani implement effici complex
product process pharmaceut compani germani also benefit close proxim lead
machin plant manufactur ensur continu product process reduc downtim germani
account approxim total product machineri plant europ
research develop
germani becom one world import countri clinic studi germani leader
industry-initi clinic studi europ second world-wide dens network univers faculti
well varieti research institut affili univers speak favor germani busi locat
benefit assess review negoti problem conflict
legislatur creat act restructur pharmaceut market amnog includ difficult
compon term mandatori discount price moratorium earli benefit assess directli
massiv impact exist busi model especi procedur earli benefit assess
establish process complex complic place question
facilit easier categor individu aspect procedur develop interact
inform graphic cooper rztezeitung illustr process earli benefit assess
includ parti involv result problem conflict
associ research-bas pharmaceut compani vfa
earli german associ research-bas pharmaceut compani vfa
vfa repres interest global leader research-bas pharmaceut compani
subsidiari affili compani healthcar research econom polici
german associ pharmaceut industri bpi
servic provid compani field biotechnolog herbal medicin homeopathy/anthroposophi
german associ produc
member member among pharmaceut industri associ
germani member primarili pharmaceut produc also pharmacist lawyer publish agenc
well market opinion research institut healthcar field
generika associ compani manufactur gener biosimilar product germani
generika member compani germani compani manufactur gener biosimilar product
togeth cover percent medicin drug requir statutori health insur fund
bundesverband der arzneimittel-herstel german medicin manufactur associ
repres interest pharmaceut industri germani compris intern compani well
local small medium enterpris sme compani membership lead trade organ
pharmaceut industri germani
cover entir rang industri landscap self-med medicin over-the-counter prescript
drug rx medic devic
advoc secur respons self-med profession medic pharmaceut advic
therefor strongli support statutori protect owner-oper pharmaci primari institut
addit commit free fair clean advertis promot principl regist
activ take part public health polici discuss compet refer public author
policymak institut german healthcar sector
member inform relev regulatori legisl procedur nation european level
offer scientif hands-on advic scientif servic organ widi
repres member european level brussels-bas aesgp associ european
self-med industri furthermor associ wsmi world self-med industri feder
member associ contin
work pharmaceut compani germani greatli hamper recent year due legisl
measur sever step tighten discount regul caus legal mandat manufactur discount
tripl sinc addit discount increas substanti recent year base individu agreement
overal manufactur receiv half sell price drug sector statutori
health insur report increas spend last year expenditur pharmaceut actual decreas
main driver behind spend pharmaceut price actual decreas year
increas consumpt result age societi avail new improv pharmaceut
treatment sever life-threaten diseas
third shi expenditur eur billion total eur billion spent hospit treatment togeth
expenditur care doctor eur billion percent pharmaceut eur billion percent
make anoth third eur billion spent administr cost increas mandatori manufactur
discount result percent decreas expenditur pharmaceut compar
associ research-bas pharmaceut compani vfa
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
